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Objective To determine antimicrobial activity against Haemophilus influenzae and Moraxella catarrhalis.
Methods A central laboratory performed NCCLS susceptibility testing for all isolates and b-lactamase and
capsular serotype determinations for H. influenzae.
Results A total of 2712 H. influenzae and 1079 M. catarrhalis were collected. H. influenzae susceptibilities were
>90% for amoxicillin/clavulanate, cefaclor, loracarbef, cefprozil, cefuroxime, ciprofloxacin, azithromycin
and clarithromycin and were <80% for trimethoprim/sulfamethoxazole and ampicillin. 19.3% were
b-lactamase positive. The most common serotype was type-b (5.6%); 86.1% were nontypeable. M. catarrhalis
had MIC90 within therapeutic range for all antimicrobials except ampicillin.
Conclusion The conclusion of the study is that antimicrobials, except ampicillin and trimethoprim/
sulfamethoxazole, remain good empiric choices against H. influenzae and M. catarrhalis.
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b-lactamase
Accepted 1 August 2001
Clin Microbiol Infect 2001; 7: 671–677
Haemophilus influenzae and Moraxella catarrhalis are common
pathogens for community-acquired respiratory tract infections
including acute exacerbation of chronic bronchitis, acute otitis
media, sinusitis and pneumonia. Due to the pressures of anti-
microbial treatment, there is growing concern over the spread
of resistant pathogens throughout many parts of the world due
to the emergence and dissemination of antimicrobial resistance
mechanisms. For H. influenzae and M. catarrhalis, these concerns
have focused primarily on the production and spread of various
types of b-lactamases. The clinical impact of these in some parts
of the world has resulted in a narrowing of the treatment options
reflected in treatment guidelines and has dramatically increased
the costs of patient management [1,2].
Weundertookamultinationalsurveillancestudytoexaminethe
activity of 10 commonly prescribed oral antimicrobial agents
against isolates of H. influenzae and M. catarrhalis from 30 geo-
graphically diverse study centers in 13 countries from Europe,
Asia, Australia, the Middle East and North America where there
was an expressed common interest in suchdata. Four centers were
from Belgium; three each from China, the Czech Republic,
Greece, Pakistan and Turkey; two each from Australia, Korea,
Poland and the Slovak Republic; and one each from Egypt,
Mexico and Portugal. Each center was instructed to collect
prospectively up to 100 isolates of H. influenzae and 50 isolates
of M. catarrhalis from July 1999 to August 2000. Isolates were
considered ‘clinically relevant’ andwere included in the studyonly
if they were documented as the primary etiologic agent of the
patient’s current infection for which the patient was receiving
antimicrobial therapy. Organismswere collected and identifiedby
each laboratory’s local standard operating procedures. A pure
culture isolate was subcultured onto chocolate agar slants, incu-
bated at 35 8C for 18–24 h and shipped at ambient temperature to
the central laboratory. Each isolate was quality controlled for
purity and characteristic morphology and re-identified by either
Haemophilus IDAgar Quad (X and V factors) or oxidase spot and
butyrate esterase disk test (Remel, Lenexa, KS) when identifica-
tion was questionable.
The minimum inhibitory concentrations (MICs) for ampi-
cillin, amoxicillin/clavulanate, cefaclor, loracarbef, cefprozil,
cefuroxime, azithromycin, clarithromycin, ciprofloxacin and
trimethoprim/sulfamethoxazole were determined using broth
microdilution following guidelines according to the NCCLS
M7-A5 [3]. All isolates were tested on dehydrated-micro-
broth 96-well panels prepared commercially by Dade-Micro-
Scan, Inc. Susceptibility testing media included Haemophilus
test medium (PML Laboratories, Wilsonville, OR, USA) for
H. influenzae and cation-adjusted (Ca2þ, 25 mg/L; Mg2þ,
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12.5 mg/L) Mueller Hinton broth (PML Laboratories) for M.
catarrhalis [3]. Each antimicrobial panel was inoculated with
100mL of a standard bacterial suspension of approximately
5 105 colony-forming units (CFU)/mL and incubated at
35 8C in ambient air for 24 h. Quality control organisms (H.
influenzaeATCC49247andATCC49766)wereincluded ineach
set of MIC determinations [3]. Testing for the presence of b-
lactamase production was conducted only on isolates of Haemo-
philus using the Cefinase disk test (Becton Dickinson Microbiol-
ogy Systems, Cockeysville, MD, USA). Serological typing of H.
influenzae was performed using the slide agglutination technique
asdescribedbythemanufacturerwithBactoH.influenzaeantisera
(Difco Laboratories, Detroit, MI, USA).
In this global study, 3791 isolates were collected, 2712 H.
influenzae and 1079 M. catarrhalis. The isolates were from
community-acquired infections of which out-patients account-
ed for 65.4% (2479 isolates), in-patients for 32.3% (1223 isolates)
and 2.3% were not specified. Isolates were collected from
individuals ranging in age from 1 to 98 years of age with a
mode of 4 years and a study mean of 30 years. Overall, 1879
(49.5%) isolates were from patients 18 years of age, 1221
(32.2%) from patients 19–65 and 638 (16.8%) from patients
>65 years of age while 57 (1.5%) had no age specified. The
majority of all the isolates, 91.5%, were from respiratory tract
infections, 70.1% of which were specified as sputum cultures,
14.9% as throat swabs and 6.5% as ear specimens. There were
also 116 (3.1%) eye isolates, 60 (1.6%) blood cultures and 143
(3.8%) isolates from other sources.
The results of this study demonstrated an overall rate of b-
lactamase production in H. influenzae of 19.3%. These results
did not differ significantly from world-wide data collected
during 1992–96 and 2000 in which 18.1 and 17% of the isolates
were b-lactamase positive, respectively [4,5]. Considerable
variation in the incidence of b-lactamase production among
European, Asian and North American countries has been
reported in other international surveillance studies [6–8].
The prevalence of b-lactamase-positive isolates in this study
also varied greatly by country and ranged in Asia from 5.7 to
61.4% (China and Korea, respectively) and in Europe from 2.6
to 26.2% (Czech Republic and Slovak Republic, respectively).
Direct comparisons of b-lactamase production rates in Belgium
(24.8%), Mexico (30.8%) and the Czech Republic (2.6%) are
comparable to those found by Felmingham et al. in 1996 [6].
The country prevalence rates for b-lactamase-producing iso-
lates of H. influenzae resistant to ampicillin were also similar to
those presented by Staples et al. [5]. Although consistently high
rates have been seen in countries such as Spain and France in the
past several years, it is noted that rates may differ significantly
among individual centers within these countries [7,9]. Center
to center variations may explain the wide differences in b-
lactamase-positive isolates among geographically contiguous
countries such as China and Korea or the Czech Republic
and the Slovak Republic. The unexplained extremely high rate
of b-lactamase production seen in Korea would bring into
question the use of b-lactams for empiric treatment of H.
influenzae in Korea. However, due to the relatively small
number of investigative centers per country, this issue, as well
as other country-specific issues, deserve additional study.
This report presents data for one of the largest H. influenzae
studies in which serotyping has been conducted (n¼ 2676).
The majority (86.1%), of the H. influenzae isolated were non-
typeable isolates with only 13.9% as types a–f (Hia–Hif). The
prevalence of b-lactamase was significantly higher in Hib
isolates, 35.3%, compared to nontypeable isolates (18.2%)
and were more frequently isolated in children 5 years of
age, 45.3% of the time (Table 1). Prior to effective vaccination
programs, H. influenzae type-b (Hib) was the primary etiologic
agent of meningitis in children and was considered a major
cause of childhood morbidity and mortality [10]. Since the
advent of effective conjugate vaccine programs, there has been a
decrease in the prevalence of Hib and a concomitant increase in
other serotypes [11–13]. Countries that had the highest rates of
Hib, such as the Czech Republic and Pakistan, concurrently
had the lowest rates of non-Hib serotypes. Countries with the
lowest percentages of Hib serotypes, Australia, Belgium, Greece
and Korea, had significant increases in the remaining typeable
serotypes, specifically Hid and Hif. However, without detailed
knowledge of the vaccination programs within each country, no
specific conclusions or temporal relationship to such programs
can be drawn from these data. Hib was seen more frequently
(45.3%) in children<5 years of age and 65.3% were seen in the
pediatric population as a whole (less than 18 years). Contrasting
this finding, the remaining serotypes, all typeable serotypes
except Hib and nontypeable, were evenly distributed between
the adult and pediatric populations. Hib, Hid and Hif isolates
were recovered predominately from out-patient locations, as
were the nontypeable isolates. Although the data suggest in-
patient sources for Hia, Hid and Hie, the numbers are too small
to draw any meaningful conclusions.
The majority of the antimicrobials tested in this surveillance
demonstrated excellent antimicrobial activity against H. influ-
enzae. Antimicrobial susceptibility varied significantly from
country to country but appeared to be related predominately
to the presence of b-lactamase rather than to geographic
location (Table 2). This study demonstrated that antimicrobials
that have been commonly utilized over one or more decades,
such as cefaclor, azithromycin and amoxicillin/clavulanate,
continue to be effective against these major respiratory patho-
gens with aggregate susceptibilities >90%. For example, the
MIC90 of cefaclor for H. influenzae was 8 mg/L and the
percentage of H. influenzae isolates susceptible to cefaclor using
a breakpoint of8 mg/L, was 93.9% and ranged from 83.0% in
Korea to 98.8% in China. Also, azithromycin had 100% activity
in all countries with the exception of Portugal, and amoxicillin/
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Table1 H. influenzae serotyping categorized by country, age groups and in-patient/out-patient
Combined
Total
N(%)
Hia
n (%)
Hib
n (%)
Hic
n (%)
Hid
n (%)
Hie
n (%)
Hif
n (%)
Typeables
n (%)
Non-typeables
n (%)
Study totals 2676 19 (0.7) 150 (5.6) 13 (0.5) 98 (3.7) 39 (1.5) 52 (1.9) 371 (13.9) 2305 (86.1)
b-Lac-positive 515 (19.2) (0) 53 (35.3) 5 (38.5) 23 (23.5) 10 (25.6) 4 (7.7) 95 (18.4) 420 (18.2)
Country
Australia 200 (7.5) 4 (21.1) 5 (3.3) 3 (23.1) 6 (6.1) 10 (25.6) 5 (9.6) 33 (16.5) 167 (7.2)
Belgium 405 (15.1) 2 (10.5) 3 (2) 2 (15.4) 25 (25.5) 6 (15.4) 15 (28.8) 53 (13.1) 352 (15.3)
China 327 (12.2) (0) 13 (8.7) 1 (7.7) 3 (3.1) 2 (5.1) (0) 19 (5.8) 308 (13.4)
Czech Rep. 187 (7.0) 1 (5.3) 39 (26) 1 (7.7) 1 (1) (0) 2 (3.8) 44 (23.5) 143 (6.2)
Egypt 18 (0.7) (0) (0) (0) (0) (0) (0) 0 (0) 18 (0.8)
Greece 207 (7.7) 2 (10.5) 12 (8) 1 (7.7) 23 (23.5) 5 (12.8) 2 (3.8) 45 (21.7) 162 (7)
Korea 231 (8.6) 2 (10.5) 4 (2.7) 3 (23.1) 16 (16.3) 3 (7.7) 2 (3.8) 30 (13) 201 (8.7)
Mexico 145 (5.4) (0) 1 (0.7) 1 (7.7) 5 (5.1) (0) (0) 7 (4.8) 138 (6)
Pakistan 222 (8.3) (0) 32 (21.3) (0) 3 (3.1) 1 (2.6) 11 (21.2) 47 (21.2) 175 (7.6)
Poland 201 (7.5) 3 (15.8) 11 (7.3) 1 (7.7) 5 (5.1) 5 (12.8) 2 (3.8) 27 (13.4) 174 (7.5)
Portugal 204 (7.6) 1 (5.3) 3 (2) (0) 4 (4.1) 2 (5.1) 2 (3.8) 12 (5.9) 192 (8.3)
Slovak Rep. 204 (7.6) 2 (10.5) 14 (9.3) (0) 2 (2) 4 (10.3) 8 (15.4) 30 (14.7) 174 (7.5)
Turkey 125 (4.7) 2 (10.5) 13 (8.7) (0) 5 (5.1) 1 (2.6) 3 (5.8) 24 (19.2) 101 (4.4)
Age group
0^5 883 (33.0) 4 (21.1) 68 (45.3) 4 (30.8) 39 (39.8) 12 (30.8) 13 (25) 140 (37.7) 743 (32.2)
6^18 431 (16.1) 6 (31.6) 30 (20) 3 (23.1) 13 (13.3) 10 (25.6) 8 (15.4) 70 (18.9) 361 (15.7)
19^65 910 (34.0) 7 (36.8) 42 (28) 3 (23.1) 27 (27.6) 11 (28.2) 17 (32.7) 107 (28.8) 803 (34.8)
Over 65 405 (15.1) 2 (10.5) 9 (6) 2 (15.4) 18 (18.4) 5 (12.8) 13 (25) 49 (13.2) 356 (15.4)
Not given 47 (1.8) (0) 1 (0.7) 1 (7.7) 1 (1) 1 (2.6) 1 (1.9) 5 (1.3) 42 (1.8)
Location
In-patient 816 (30.5) 12 (63.2) 52 (34.7) 7 (53.8) 35 (35.7) 21 (53.8) 19 (36.5) 146 (39.4) 670 (29.1)
Out-patient 1797 (67.2) 7 (36.8) 97 (64.7) 6 (46.2) 62 (63.3) 18 (46.2) 30 (57.7) 220 (59.3) 1577 (68.4)
Not given 63 (2.4) (0) 1 (0.7) (0) 1 (1) (0) 3 (5.8) 5 (1.3) 58 (2.5)
Thirty-six isolates were nonviable upon subculture for serotyping and are not included in this table.
Table 2 MIC50, MIC90 (mg/L) and antimicrobial susceptibility of 2712 isolates ofH. influenzae and1079M. catarrhalis
MIC (mg/L) S%a
Country n Antimicrobial 50% 90% Range All b-Lac (^ ) b-Lac (þ)
H. influenzae 2712 Ampicillin 0.25 8 0.03^8 79.9 98.9 0.6
A/C 0.5 1 0.03^16 100d 100 99.8
Cefaclor 2 8 0.12^64 93.9 97.1 80.3
Loracarbef 1 8 0.06^64 93.5 96.3 81.7
Cefprozil 2 8 0.12^64 91.7 95.7 75.2
Cefuroxime 0.5 2 0.03^32 98.7 98.8 98.1
Azithromycin 1 2 0.03^16 100d 100d 100
Clarithromycin 8 8 0.03^32 94.4 94.8 92.7
Ciprofloxacin 0.015 0.015 0.002^2 99.9 99.9 100
TMP/SMX 0.25 8 0.015^8 65.5 68.4 53.6
Australia 201 Ampicillin 0.25 8 0.06^8 76.6 98.1 0.0
A/Cb 0.5 1 0.03^16 99.5 100 97.7
Cefaclor 2 8 0.25^32 92.0 93.0 88.6
Loracarbef 1 8 0.25^64 92.6 92.4 93.2
Cefprozil 2 8 0.25^32 90.1 91.7 84.1
Cefuroxime 0.5 2 0.06^8 98.5 98.1 100
Azithromycin 1 2 0.03^4 100 100 100
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Table 2 continued
MIC (mg/L) S%a
Country n Antimicrobial 50% 90% Range All b-Lac (^ ) b-Lac (þ)
Clarithromycin 8 8 0.5^16 96.0 96.2 95.5
Ciprofloxacin 0.015 0.015 0.002^1 100 100 100
TMP/SMXc 0.25 4 0.015^8 83.6 82.8 86.4
Belgium 408 Ampicillin 0.25 8 0.03^8 75.0 99.0 2.0
A/C 0.5 1 0.12^4 100 100 100
Cefaclor 2 4 0.25^32 96.1 97.4 92.1
Loracarbef 1 4 0.25^32 95.7 96.4 93.1
Cefprozil 2 8 0.25^32 95.3 96.7 91.1
Cefuroxime 0.5 2 0.12^8 98.8 99.0 98.0
Azithromycin 1 2 0.06^4 100 100 100
Clarithromycin 8 8 0.12^32 91.7 92.5 89.1
Ciprofloxacin 0.015 0.015 0.004^0.5 100 100 100
TMP/SMX 0.12 4 0.015^8 85.1 85.7 83.2
China 331 Ampicillin 0.25 5 0.03^8 94.3 99.7 5.3
A/C 0.5 1 0.03^4 100 100 100
Cefaclor 1 4 0.12^32 98.8 99.4 89.5
Loracarbef 1 4 0.12^32 98.5 99.0 89.5
Cefprozil 2 4 0.12^32 98.1 98.7 86.7
Cefuroxime 0.5 1 0.03^8 99.7 99.7 100
Azithromycin 1 2 0.03^4 100 100 100
Clarithromycin 8 8 0.12^32 93.7 94.6 78.9
Ciprofloxacin 0.015 0.06 0.002^2 99.4 99.4 100
TMP/SMX 1 8 0.015^8 46.8 47.1 42.1
Czech Republic 192 Ampicillin 0.25 0.5 0.06^8 96.9 99.5 0.0
A/C 0.25 1 0.12^2 100 100 100
Cefaclor 1 4 0.25^4 97.9 97.9 100
Loracarbef 1 2 0.25^16 97.4 97.9 80.0
Cefprozil 1 4 0.5^32 96.9 97.3 80.0
Cefuroxime 0.5 1 0.06^8 98.4 98.4 100
Azithromycin 0.5 2 0.12^2 100 100 100
Clarithromycin 4 8 1^16 98.4 98.4 100
Ciprofloxacin 0.015 0.015 0.004^0.03 100 100 100
TMP/SMX 0.25 4 0.015^8 65.1 65.2 60.0
Egypt 18 Ampicillin 0.25 0.25 0.25^0.5 100 100 ^
A/C 0.5 0.5 0.5^0.5 100 100 ^
Cefaclor 2 4 1^16 94.4 94.4 ^
Loracarbef 1 4 1^8 100 100 ^
Cefprozil 2 8 1^16 94.4 94.4 ^
Cefuroxime 1 1 0.5^2 100 100 ^
Azithromycin 1 2 0.5^2 100 100 ^
Clarithromycin 8 8 2^8 100 100 ^
Ciprofloxacin 0.015 0.015 0.008^0.015 100 100 ^
TMP/SMX 1 8 0.12^8 33.3 33.3 ^
Greece 208 Ampicillin 0.25 8 0.06^8 82.2 98.8 0.0
A/C 0.5 1 0.06^4 100 100 100
Cefaclor 2 4 0.5^64 97.1 98.3 91.4
Loracarbef 2 4 0.25^64 96.2 97.1 91.4
Cefprozil 2 8 0.12^64 95.1 98.2 80.0
Cefuroxime 0.5 2 0.03^8 99.5 99.4 100
Azithromycin 1 2 0.03^4 100 100 100
Clarithromycin 8 8 0.12^16 93.8 92.5 100
Ciprofloxacin 0.015 0.015 0.004^0.25 100 100 100
TMP/SMX 0.25 8 0.015^8 79.3 80.3 74.3
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Table 2 continued
MIC (mg/L) S%a
Country n Antimicrobial 50% 90% Range All b-Lac (^ ) b-Lac (þ)
Korea 236 Ampicillin 8 8 0.03^8 37.7 97.8 0.0
A/C 0.5 2 0.06^4 100 100 100
Cefaclor 4 16 0.12^64 83.1 96.7 74.5
Loracarbef 2 16 0.06^64 83.1 96.7 74.5
Cefprozil 4 16 0.12^64 77.5 96.7 65.5
Cefuroxime 1 2 0.06^8 97.5 100 95.9
Azithromycin 1 2 0.03^4 100 100 100
Clarithromycin 8 8 0.03^32 92.8 92.3 93.1
Ciprofloxacin 0.015 0.015 0.004^1 100 100 100
TMP/SMX 1 8 0.03^8 48.3 69.2 35.2
Mexico 146 Ampicillin 0.5 8 0.12^8 67.8 98.0 0.0
A/C 0.5 2 0.06^2 100 100 100
Cefaclor 4 16 0. 25^64 85.6 100 53.3
Loracarbef 4 16 0. 25^64 86.3 100 55.6
Cefprozil 4 16 0. 25^64 87.7 99.0 62.2
Cefuroxime 1 1 0. 25^4 100 100 100
Azithromycin 1 1 0. 25^2 100 100 100
Clarithromycin 8 8 2^16 97.3 100 91.1
Ciprofloxacin 0.015 0.015 0.004^0.5 100 100 100
TMP/SMX 0.25 8 0.03^8 53.4 52.5 55.6
Pakistan 223 Ampicillin 0.25 8 0.12^8 83.4 98.4 0.0
A/C 0.5 0.5 0.12^1 100 100 100
Cefaclor 2 8 0.5^64 95.5 95.2 97.1
Loracarbef 2 8 0.25^64 94.2 94.2 94.1
Cefprozil 4 16 0.25^64 89.7 89.9 88.2
Cefuroxime 0.5 2 0.12^32 96.0 95.8 97.1
Azithromycin 0.5 1 0.06^1 100 100 100
Clarithromycin 4 8 0.15^8 100 100 100
Ciprofloxacin 0.015 0.015 0.002^0.03 100 100 100
TMP/SMX 1 8 0.015^8 47.1 55.6 0.0
Poland 202 Ampicillin 0.25 0.5 0.03^8 96.5 100 0.0
A/C 0.5 1 0.06^2 100 100 100
Cefaclor 2 4 0.25^32 98.0 98.5 85.7
Loracarbef 1 4 0.25^32 97.5 97.9 85.7
Cefprozil 1 4 0.25^64 96.5 97.4 71.4
Cefuroxime 0.5 2 0.12^4 100 100 100
Azithromycin 1 2 0.03^4 100 100 100
Clarithromycin 8 8 0.12^32 92.6 92.3 100
Ciprofloxacin 0.015 0.015 0.004^0.03 100 100 100
TMP/SMX 0.25 8 0.015^8 68.8 69.7 42.9
Portugal 212 Ampicillin 0.25 8 0.12^8 83.5 96.7 0.0
A/C 0.5 2 0.03^4 100 100 100
Cefaclor 2 16 0.5^64 88.7 91.8 69.0
Loracarbef 2 16 0.5^64 86.8 89.6 69.0
Cefprozil 2 16 0.5^64 86.3 89.6 65.5
Cefuroxime 1 4 0.12^32 97.6 97.3 100
Azithromycin 1 2 0.03^16 99.5 99.5 100
Clarithromycin 8 8 0.12^32 92.0 91.8 93.1
Ciprofloxacin 0.015 0.015 0.004^1 100 100 100
TMP/SMX 0.25 8 0.03^8 67.0 66.1 72.4
Slovak Republic 214 Ampicillin 0.25 8 0.12^8 73.3 99.3 0.0
A/C 0.5 1 0.12^4 100 100 100
Cefaclor 2 8 0.5^32 91.8 98.0 74.1
 2001 Copyright by the European Society of Clinical Microbiology and Infectious Diseases, CMI, 7, 671–677
Turnak et al Antimicrobial susceptibilities of H. influenzae and M. catarrhalis 675
clavulanate was 100% active against H. influenzae in all countries
except Australia. Additionally, this study identified three b-
lactamase-negative, ampicillin-resistant and three ciprofloxacin-
resistant H. influenzae (0.1% each). The prevalence of these
isolates is similar to that in other published data [14,15].
There were 1079 M. catarrhalis isolates tested in this study
(Table 2). b-Lactamase production was not determined since
this is the only important resistance mechanism for this species
and has been repeatedly shown to be in excess of 90% regardless
of region or country [8,16,17]. The antimicrobials in this study
inhibited 90% (MIC90) of M. catarrhalis isolates at the following
concentrations: ampicillin, 4 mg/L; amoxicillin/clavulanate,
0.25 mg/L; cefaclor, 1 mg/L; loracarbef, 2 mg/L; cefprozil,
4 mg/L; cefuroxime, 2 mg/L; azithromycin, 0.06 mg/L; clarith-
romycin, 0.12 mg/L; ciprofloxacin, 0.03 mg/L; trimethoprim/
sulfamethoxazole, 0.25 mg/L. Only ampicillin was considered
inactive against M. catarrhalis with an MIC50 of 1 mg/L and a
MIC90 of 4 mg/L.
This multicenter, multinational study demonstrated the
continued in vitro activity of commonly utilized antimicrobials,
such as cefaclor, azithromycin and amoxicillin/clavulanate,
against H. influenzae and M. catarrhalis. This study also points
out the variable nature of b-lactamase production among
countries, the changes in frequency and nature of H. influenzae
serotypes, and the essential need for surveillance programs as a
guideline for empiric treatment of these two common respira-
tory pathogens.
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Table 2 continued
MIC (mg/L) S%a
Country n Antimicrobial 50% 90% Range All b-Lac (^ ) b-Lac (þ)
Loracarbef 2 8 0.5^32 91.8 95.4 81.5
Cefprozil 2 16 0.5^32 87.4 95.4 64.8
Cefuroxime 0.5 2 0.12^8 98.5 98.7 98.1
Azithromycin 1 2 0.03^4 100 100 100
Clarithromycin 8 8 1^32 94.2 94.7 92.6
Ciprofloxacin 0.015 0.015 0.008^2 99.5 99.3 100
TMP/SMX 0.25 8 0.015^8 70.9 82.2 38.9
Turkey 266 Ampicillin 0.25 1 0.06^8 95.4 100 0.0
A/C 0.5 1 0.06^4 100 100 100
Cefaclor 2 4 0.12^64 97.7 99.2 66.7
Loracarbef 1 4 0.12^64 97.7 98.4 83.3
Cefprozil 2 8 0.12^16 96.9 97.6 83.3
Cefuroxime 0.5 2 0.03^4 100 100 100
Azithromycin 1 2 0.03^4 100 100 100
Clarithromycin 8 8 0.06^32 94.6 95.1 83.3
Ciprofloxacin 0.015 0.015 0.004^0.12 100 100 100
TMP/SMX 0.25 8 0.015^8 67.4 69.9 16.7
M. catarrhalis 1079 Ampicillin 1 4 0.03^8 n/a ^ ^
A/Cb 0.12 0.25 0.03^8 n/a ^ ^
Cefaclor 0.5 1 0.06^16 n/a ^ ^
Loracarbef 1 2 0.06^32 n/a ^ ^
Cefprozil 2 4 0.25^32 n/a ^ ^
Cefuroxime 1 2 0.03^8 n/a ^ ^
Azithromycin 0.03 0.06 0.03^2 n/a ^ ^
Clarithromycin 0.12 0.12 0.03^2 n/a ^ ^
Ciprofloxacin 0.03 0.03 0.002^0.25 n/a ^ ^
TMP/SMXc 0.12 0.25 0.015^8 n/a ^ ^
a Percentage of susceptible breakpoint criteria used interpretive standards for H. influenzae or ‘n/a’ (not applicable) where no interpretive criteria exist forM.
catarrhalis (NCCLSM100-S10, 2000); bAmoxicillin/clavulanate; cTrimethoprim/sulfamethoxazole; d100%was due to rounding up from 99.99.
 2001 Copyright by the European Society of Clinical Microbiology and Infectious Diseases, CMI, 7, 671–677
676 Clinical Microbiology and Infection, Volume 7 Number 12, December 2001
(Center Hospitalier Universitai), Pierre Delannoy (Laboratoire
de Biologie Clinique et Hormonale), and Marc Lontie
(MCH); China, Hu Yunjian (Beijing Hospital), Minjun Chen
(Peking Union Medical College Hospital), and Yuxing Ni
(Rui Jin Hospital); Czech Republic, Otakar Nyc (FN Motol),
AnnaJedlickova (General Faculty Hospital), and Pavla
Urbaskova (National Reference Laboratory for Antibiotics);
Egypt, Momena Kamel (MKL Clinical Pathology Lab);
Greece, Vassiliki Syriopoulou (Agia Sophia Children’s Hospital),
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